Abstract
Despite advances in antimicrobial therapy, community-acquired pneumonia (CAP) remains a common and potentially life-threatening infection. Fluoroquinolones appear to be a valid monotherapy alternative to the combination beta-lactam/macrolide therapy for non-severe hospitalised CAP, particularly in regions with a high prevalence of penicillin-resistant Streptococcus pneumoniae (PRSP) or in patients with a clinical risk of PRSP, and a key partner in the combination therapy given in casesof severe and intensive care unit-admitted CAP and when Pseudomonas aeruginosa infection is suspected. The high bioavailability of fluoroquinolones facilitates an early switch from intravenous to oral therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 61-65 |
| Number of pages | 5 |
| Journal | European Respiratory Disease |
| Volume | 8 |
| Issue number | 1 |
| Publication status | Published - Mar 2012 |
Keywords
- Antibiotic resistance
- Community-acquired pneumonia
- Fluoroquinolones
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Fingerprint Dive into the research topics of 'The role of fluoroquinolones in the treatment of patients hospitalised with community-acquired pneumonia'. Together they form a unique fingerprint.
Cite this
Blasi, F., Piffer, F., Zanardelli, M., & Tarsia, P. (2012). The role of fluoroquinolones in the treatment of patients hospitalised with community-acquired pneumonia. European Respiratory Disease, 8(1), 61-65.